B. Riley analyst Kalpit Patel lowered the firm’s price target on Kymera Therapeutics to $35 from $50 and keeps a Neutral rating on the shares. The analyst says Pfizer’s recent IRAK4 inhibitor failure weighs on his outlook for IRAK4 as a target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on KYMR:
- Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update
- Kymera Therapeutics director sells $8.7M in common stock
- Kymera Therapeutics to Report Third Quarter 2022 Results on November 3
- Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline
- Guggenheim to hold a conference